Demographic and hematologic characteristics at first pregnancy of 58 women with ET
| Characteristic . | . |
|---|---|
| No. of patients | 58 |
| No. of pregnancies | 96 |
| Median age at diagnosis, y (range) | 28 (18-44) |
| Median age at conception, y (range) | 32 (18-44) |
| No. with at least 1 abortion risk factor (%)* | 10/58 (17) |
| No. with thrombophilia | 15/46 (33) |
| Factor V Leiden mutation; +/−† | 1 |
| Methylenetetrahydrofolate reductase mutation; +/+† | 7 |
| Prothrombin mutation; +/−† | 1 |
| Hyperhomocysteinemia‡ | 4 |
| Antiphospholipid antibody | 2 |
| No. with JAK2 (617V>F) mutation (%) | 24/49 (49) |
| Median JAK2 (617V>F) mutation burden, % (range) | 10.1 (3.9-24.2) |
| Median WBC count at pregnancy, × 109/L (range) | 7.1 (4.2-15.3) |
| Median hemoglobin level at pregnancy, g/L (range) | 131 (115-154) |
| Median platelet count at pregnancy, × 109/L (range) | 601 (266-1660) |
| Characteristic . | . |
|---|---|
| No. of patients | 58 |
| No. of pregnancies | 96 |
| Median age at diagnosis, y (range) | 28 (18-44) |
| Median age at conception, y (range) | 32 (18-44) |
| No. with at least 1 abortion risk factor (%)* | 10/58 (17) |
| No. with thrombophilia | 15/46 (33) |
| Factor V Leiden mutation; +/−† | 1 |
| Methylenetetrahydrofolate reductase mutation; +/+† | 7 |
| Prothrombin mutation; +/−† | 1 |
| Hyperhomocysteinemia‡ | 4 |
| Antiphospholipid antibody | 2 |
| No. with JAK2 (617V>F) mutation (%) | 24/49 (49) |
| Median JAK2 (617V>F) mutation burden, % (range) | 10.1 (3.9-24.2) |
| Median WBC count at pregnancy, × 109/L (range) | 7.1 (4.2-15.3) |
| Median hemoglobin level at pregnancy, g/L (range) | 131 (115-154) |
| Median platelet count at pregnancy, × 109/L (range) | 601 (266-1660) |